Disposition of 500000 shares by Booth Andrew of Abcellera Biologics at 0.32 subject to Rule 16b-3
ABCL Stock | USD 3.18 0.05 1.55% |
About 55% of Abcellera Biologics' institutional investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Abcellera Biologics suggests that some traders are interested. Abcellera Biologics' investing sentiment shows overall attitude of investors towards Abcellera Biologics.
Abcellera |
Filed transaction by Abcellera Biologics Officer: Chief Financial Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Cash Flow Correlation
Abcellera Biologics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Abcellera Biologics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Abcellera Biologics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Abcellera Biologics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Abcellera Biologics Maximum Pain Price Across April 17th 2025 Option Contracts
Abcellera Biologics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Abcellera Biologics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Abcellera Biologics' options.
Abcellera Biologics Fundamental Analysis
We analyze Abcellera Biologics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Abcellera Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Abcellera Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
Abcellera Biologics is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Abcellera Biologics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Abcellera Biologics stock to make a market-neutral strategy. Peer analysis of Abcellera Biologics could also be used in its relative valuation, which is a method of valuing Abcellera Biologics by comparing valuation metrics with similar companies.
Peers
Abcellera Biologics Related Equities
PPCB | Propanc Biopharma | 108.33 | ||||
KRYS | Krystal Biotech | 3.23 | ||||
PTCT | PTC Therapeutics | 2.06 | ||||
MDGL | Madrigal Pharmaceuticals | 0.19 | ||||
SRPT | Sarepta Therapeutics | 0.87 | ||||
CVAC | CureVac NV | 1.29 | ||||
IOVA | Iovance Biotherapeutics | 1.94 | ||||
VIR | Vir Biotechnology | 5.41 | ||||
HEPA | Hepion Pharmaceuticals | 8.74 |
Check out Abcellera Biologics Hype Analysis, Abcellera Biologics Correlation and Abcellera Biologics Performance. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.459 | Earnings Share (0.61) | Revenue Per Share | Quarterly Revenue Growth (0.01) | Return On Assets |
The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.